1 Reason I'm Seriously Considering Novo Nordisk as a Buy‑and‑Never‑Sell Obesity Stock

Core Insights - Novo Nordisk's GLP-1 drug Ozempic gained significant traction after the introduction of Wegovy in 2021, leading to a 60% increase in stock price that year [1] - In 2022, total sales growth reached 18%, with net income growing by 9% due to investments in production capacity; however, 2023 saw a sales surge of 35% and profits up by 55% before facing competition from Eli Lilly's products in 2024 [2] - The stock price peaked above $142 in 2024 but has since fallen to around $47, representing a 67% decline from its peak [3] Sales and Market Dynamics - The introduction of oral versions of Wegovy and Ozempic has reinvigorated interest in Novo Nordisk, with FDA approvals for these new forms occurring recently [5] - Eli Lilly is expected to quickly catch up with its own GLP-1 pills, with an FDA decision on a Mounjaro pill anticipated in the second quarter of the year [6] - Novo Nordisk is aware of the competitive landscape and is likely to intensify efforts to maintain market share in the oral GLP-1 segment [7]